We are very happy to let you know that McRoberts is part of the winning consortium of the IMI2 - Call 13 Topic 7! The project is part of the Innovative Medicines Initiative Joint Undertaking, a unique partnership between the European Community and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The five-year project is called ‘Linking digital assessment of mobility to clinical endpoints to drive regulatory acceptance and clinical practice’. To ensure full acceptance and integration of digital mobility assessment into clinical trials and utilisation as primary or secondary endpoint, there is a need for rigorous validation and linkage to clinically relevant ‘hard’ endpoints, such as death, disability, falls, or other complications.
McRoberts will provide state of the art activity monitors for both technical validation and clinical validation. We have extensive experience in the assessment of physical activity in COPD, Neurology and Orthopedics and our MoveMonitor has been used in various clinical trials. McRoberts’ infrastructure for data collection, which is designed to support multi-centre studies, will be utilized in the current Project as well.